Ling-Mei Wang

Chairman and CEO
Steminent Biotherapeutics Inc.

Dr. Ling-Mei Wang, the Chair and President of Steminent Biotherapeutics Inc. (SBI), trained as a cell and molecular biologist, has over 25 years of extensive experiences in research and management in a wide spectrum of research areas and has worked in both academic and industrial sectors.  Prior to joining SBI, Dr. Wang held a list of managerial positions including the Vice-President of CHO Pharma Inc., the Chief Operation Officer of Taiwan Supra Integration and Incubation Center (Si2C), the Deputy General Director and the Chief Scientific Officer at Biomedical Technology and Device Research Laboratories of Industrial Technology Research Institute (ITRI), the Associate Principal Investigator at the Institute of Molecular Genomics of National Health Research Institute (NHRI), and the Director of Research and Developlent at Vita Genomics.  Dr. Wang received her Ph.D. degree from University of Texas Health Science Center at San Antonio, USA, and was a researcher at National Cancer Institute in USA for 10 years before returning to Taiwan.

 

Speech title & Synopsis

Emerging Company of the Year

Steminent Biotherapeutics Inc. is a clinical phase biopharmaceutical company with Headquarter and major operations in Taipei, Taiwan and a Subsidiary San Diego, USA.  With the established allogenic MSC-based platform technologies, we aim to develop novel living cellular therapeutics for clinical unmet needs with initial focuses on neuro degenerative and life-threatening diseases.
Stemchymal® is Steminent’s proprietary technology platform generating the off shelf, standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.  The most advance program of Stemchymal® is the therapeutics for polyglutamine Spinocerebellar Ataxia (PolyQ SCA).  PolyQ SCA is a rare neurodegenerative disease that cause progressive difficulty with coordination. Currently, no curative therapy has been approved which can delay or halt the progression of the disease.  Steminent has completed a phase I/II and a phase II clinical trials in Taiwan.  Steminent’s partner REPROCELL has also completed a phase II clinical trial in Japan.  Armed with the superior safety data and the positive result from clinical trial outcomes, our immediate goal is partnering REPROCELL to obtain conditional market approval in Japan.
Steminent seeks to translate our evidence-based technology platform into numerous cellular therapeutic candidates and to advance the clinical potentials through global partnering initiatives. Our ultimate goal is to bring the values to the patients, medical practitioners, our partners as well as shareholders.